InvestorsHub Logo
Post# of 252255
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: mr_o post# 208985

Saturday, 02/11/2017 5:37:21 PM

Saturday, February 11, 2017 5:37:21 PM

Post# of 252255
SRPT:

I don't have any specific revenue projects in the short term. I am general a very long term shareholder so I look at this way:
~1500 Exon 51 Amenable patients in the US
Say can get 2/3 reimbursed
Average price I think will be 500k++ (wouldn't be surprised at 600-700 especially if can get non-ambulatory reimbursed).
Their EV assuming 150-200M for Voucher is a bit over 1B
So looking at 500M+ opportunity for US and putting no value on everything else (Europe, x-EU/US, pipeline) the company is 2x peek US only sales which I think they can get too relatively soon (~2-3 years).

I didn't mention another thing I really like about Ed Kaye is his style/approach not just with dealing with regulators (which is much better than his predecessor), licensing/partnering but other aspects too like willingness to negotiate a royalty with BMRN.

Those are all rough back of the hand calculations. With some luck on reimbursement and penetration may get double that in peek sales. So I see a lot of upside potential to the stock and again we are just talking US Exondys 51

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.